Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 121 Published: March 31, 2022 Report Code: GMDGDHC22043TDB

Proto-oncogene tyrosine-protein kinase Src or proto-oncogene c-Src is a non-receptor tyrosine kinase protein that is encoded by the SRC gene. It participates in signaling pathways that control a diverse spectrum of biological activities. It plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1.

The Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) Development market research report provides an in-depth analysis of Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information on the Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

Mechanisms of Action of Proto Oncogene Tyrosine Protein Kinase Src Pipeline Market

The mechanism of action of the Proto Oncogene Tyrosine Protein Kinase Src pipeline market is Proto Oncogene Tyrosine Protein Kinase Src Inhibitor.

Routes of Administration in Proto Oncogene Tyrosine Protein Kinase Src Pipeline Market

The routes of administration in the Proto Oncogene Tyrosine Protein Kinase Src pipeline market are oral, intravenous, and inhalational.

Proto Oncogene Tyrosine Protein Kinase Src pipeline market, by routes of administration

Proto Oncogene Tyrosine Protein Kinase Src pipeline market, by routes of administration

For more routes of administration insights, download a free report sample

Molecule Types in Proto Oncogene Tyrosine Protein Kinase Src Pipeline Market

The molecule type in the Proto Oncogene Tyrosine Protein Kinase Src pipeline market is small molecule.

Key Proto Oncogene Tyrosine Protein Kinase Src Pipeline Market Companies

Some of the key companies in the Proto Oncogene Tyrosine Protein Kinase Src pipeline market are Turning Point Therapeutics Inc, AbbVie Inc, AstraZeneca Plc, Avalyn Pharma Inc, Boehringer Ingelheim International GmbH, Chengdu Fanxi Biopharma Co Ltd, Fratagene Therapeutics Srl, KeifeRx LLC, Lead Discovery Center GmbH, and Nanocopoeia LLC.

Proto Oncogene Tyrosine Protein Kinase Src pipeline market, by companies

Proto Oncogene Tyrosine Protein Kinase Src pipeline market, by companies

To know more about key companies, download a free report sample

Market report overview

Mechanism of Action Proto Oncogene Tyrosine Protein Kinase Src Inhibitor
Routes of Administration Oral, Intravenous, and Inhalational
Molecule Type Small Molecule
Key Companies AbbVie Inc, AstraZeneca Plc, Avalyn Pharma Inc, Boehringer Ingelheim International GmbH, Chengdu Fanxi Biopharma Co Ltd, Fratagene Therapeutics Srl, KeifeRx LLC, Lead Discovery Center GmbH, Nanocopoeia LLC, and Prous Institute for Biomedical Research SA

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2).
  • Reviews of Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) therapeutics and enlists all their major and minor projects.
  • Assessment of Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • Summaries of all the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2).

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Identify and understand the targeted therapy areas and indications for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2).
  • Identify the use of drugs for target identification and drug repurposing.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) development landscape.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Key Players

AbbVie Inc

AstraZeneca Plc

Avalyn Pharma Inc

Boehringer Ingelheim International GmbH

Chengdu Fanxi Biopharma Co Ltd

Fratagene Therapeutics Srl

KeifeRx LLC

Lead Discovery Center GmbH

Nanocopoeia LLC

Prous Institute for Biomedical Research SA

Taiwan Liposome Co Ltd

Turning Point Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) – Overview

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) – Companies Involved in Therapeutics Development

AbbVie Inc

AstraZeneca Plc

Avalyn Pharma Inc

Boehringer Ingelheim International GmbH

Chengdu Fanxi Biopharma Co Ltd

Fratagene Therapeutics Srl

KeifeRx LLC

Lead Discovery Center GmbH

Nanocopoeia LLC

Prous Institute for Biomedical Research SA

Taiwan Liposome Co Ltd

Turning Point Therapeutics Inc

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) – Drug Profiles

bosutinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

dasatinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

Drugs to Inhibit SRC for Friedreich Ataxia – Drug Profile

Product Description

Mechanism Of Action

FNX-006 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ilorasertib – Drug Profile

Product Description

Mechanism Of Action

History of Events

JRP-890 – Drug Profile

Product Description

Mechanism Of Action

nintedanib – Drug Profile

Product Description

Mechanism Of Action

History of Events

nintedanib – Drug Profile

Product Description

Mechanism Of Action

History of Events

Ofev – Drug Profile

Product Description

Mechanism Of Action

History of Events

repotrectinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

saracatinib difumarate – Drug Profile

Product Description

Mechanism Of Action

History of Events

Si-306 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit IGF1R and SRC for Non-Small Cell Lung Cancer – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit SRC for Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

TPX-0022 – Drug Profile

Product Description

Mechanism Of Action

History of Events

TPX-0046 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Vargatef – Drug Profile

Product Description

Mechanism Of Action

History of Events

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) – Dormant Products

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) – Discontinued Products

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) – Product Development Milestones

Featured News & Press Releases

Feb 17, 2022: Zai Lab announces breakthrough therapy designation granted for Repotrectinib in China

Feb 15, 2022: Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV (nintedanib) for PF-ILD

Jan 20, 2022: Turning Point Therapeutics announces FDA clearance of investigational new drug (IND) application for combination of elzovantinib and aumolertinib in EGFR mutant met-amplified non-small cell lung Cancer

Oct 23, 2021: Turning Point Therapeutics presents early clinical data for Repotrectinib from care study in pediatric and young adult patients at SIOP 2021 Virtual Congress

Oct 13, 2021: Turning Point Therapeutics and EQRx announce clinical collaboration to evaluate elzovantinib in combination with aumolertinib in patients with EGFR mutant met-amplified advanced non-small cell lung cancer

Oct 11, 2021: Turning Point Therapeutics to present early clinical data for repotrectinib from the CARE study in pediatric and young adult patients at SIOP 2021 Virtual Congress

Oct 08, 2021: Turning Point Therapeutics presents TRIDENT-1 study clinical data for repotrectinib in NTRK+ advanced solid tumors in plenary session at 2021 AACR-NCI-EORTC Conference

Oct 04, 2021: Turning Point Therapeutics granted Breakthrough Therapy Designation for Repotrectinib treatment in patients with NTRK-positive, TKI-pretreated advanced solid tumors

Sep 30, 2021: Turning Point Therapeutics announces additional details for three data presentations at the 2021 AACR-NCI-EORTC conference

Sep 08, 2021: Turning Point Therapeutics announces early clinical data for Repotrectinib in NTRK fusion-positive advanced solid tumors selected for late-breaker plenary presentation at 2021 AACR-NCI-EORTC conference

Aug 16, 2021: Turning Point Therapeutics initiates TRIDENT-2 clinical study investigating Repotrectinib-Trametinib combination in KRAS G12D mutated advanced solid tumors

Aug 11, 2021: Turning Point Therapeutics granted sixth regulatory designation for Repotrectinib

Jun 17, 2021: Turning Point Therapeutics granted FDA Orphan Drug Designation for TPX-0022 in gastric cancer

May 28, 2021: Zai Lab announces first patient treated in China in the registrational phase 2 TRIDENT-1 study of repotrectinib

May 14, 2021: Study analysis available during ATS 2021 supports long-term treatment with Ofev in patients with systemic sclerosis-associated interstitial lung disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Indications, 2022 (Contd..2)

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by AbbVie Inc, 2022

Pipeline by AstraZeneca Plc, 2022

Pipeline by Avalyn Pharma Inc, 2022

Pipeline by Boehringer Ingelheim International GmbH, 2022

Pipeline by Chengdu Fanxi Biopharma Co Ltd, 2022

Pipeline by Fratagene Therapeutics Srl, 2022

Pipeline by KeifeRx LLC, 2022

Pipeline by Lead Discovery Center GmbH, 2022

Pipeline by Nanocopoeia LLC, 2022

Pipeline by Prous Institute for Biomedical Research SA, 2022

Pipeline by Taiwan Liposome Co Ltd, 2022

Pipeline by Turning Point Therapeutics Inc, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Dormant Products, 2022 (Contd..2)

Dormant Products, 2022 (Contd..3)

Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Frequently Asked Questions

Enquire Before Buying
$3500

Can be used by individual purchaser only

$10500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.